bristol-myers glp-1 receptor agonist products Market Size, Trends and Share Report 2026 S-1/A

Neither the author nor the publisher assumes liability for the use, interpretation, or implementation of the information contained within this article across third-party platforms

10.1007/s00125-008-1149-y 21 De MarinisY

Gallwitz, Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes, Diabetes Metab

In the mesolimbic system, GLP-1R activation has been shown to attenuate the rewarding effects of palatable food and addictive substances, indicating potential therapeutic applications for GLP-1R agonists in treating obesity and SUDs [19,20,21]

By potentially dampening inflammatory processes, GLP-1 receptor agonists may help stabilise atherosclerotic plaques, improve endothelial function, and reduce thrombotic risk

He is on a data monitoring and safety board for Inventiva